

What is claimed is:

1. A method of improving skin quality comprising topically applying to the skin an IRM compound in an amount effective to improve the quality of the skin.
2. The method of claim 1 wherein the IRM compound is an agonist of at least one TLR.
3. The method of claim 2 wherein the IRM compound is an agonist of TLR7, TLR8, or both TLR7 and TLR8.
4. The method of claim 1 wherein the IRM compound is administered via a topical application vehicle.
5. The method of claim 4 wherein the topical application vehicle comprises a cream, a foam, a gel, a spray, an ointment, a lotion, a solution, a suspension, a dispersion, an emulsion, a microemulsion, a paste, a powder, a wipe, or an oil.
6. The method of claim 1 wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof.
7. A method of visibly reducing a skin change associated with aging comprising: topically applying to skin exhibiting a change associated with aging an IRM compound in an amount and for a period of time sufficient to visibly reduce the skin change associated with aging, wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an

oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof.

5 8. A method of visibly reducing a human skin wrinkle comprising:
 topically applying to the human skin wrinkle an IRM compound in an amount
 and for a period of time sufficient to visibly reduce the wrinkle; wherein the IRM
 compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an
 imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused
10 cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a
 tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline
 amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine
 amine, a thiazolonaphthyridine amine, or a combination thereof.

15 9. A method of treating aging related skin conditions comprising:
 topically applying to the skin an IRM compound for a period of time and in an
 amount sufficient to effect changes in the dermis, wherein the IRM compound is an
 imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine
 amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine
20 amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an
 oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a
 thiazolopyridine amine, an oxazonaphthyridine amine, a thiazolonaphthyridine
 amine, or a combination thereof.

25 10. A method for reducing the appearance of skin changes associated with aging
 comprising:
 topically applying to an area of skin exhibiting skin changes associated with
 aging an IRM compound in an amount and for a period of time sufficient to reduce the
 appearance of said skin changes associated with aging, wherein the IRM compound is
30 an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine
 amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine
 amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an
 oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a

thiazolopyridine amine, an oxazolophthyridine amine, a thiazolophthyridine amine, or a combination thereof.

11. A method for improving the quality of facial skin comprising:
- 5 topically applying to facial skin an IRM compound in an amount and for a period of time sufficient to reverse or prevent changes in the dermis, where the changes in the dermis include diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, and combination thereof, and wherein
- 10 the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolophthyridine
- 15 amine, a thiazolophthyridine amine, or a combination thereof.